Tirzepatide vs Retatrutide

Tirzepatide is a dual GIP/GLP-1 receptor agonist, sold as Mounjaro (diabetes) and Zepbound (obesity). It targets two incretin hormones simultaneously, producing greater weight loss than semaglutide in head-to-head trials (up to 22.5% vs 15%). GIP activation enhances fat metabolism and may improve tolerability compared to GLP-1-only drugs.

Retatrutide is the first triple-agonist peptide, targeting GLP-1, GIP, and glucagon receptors simultaneously — earning it the nickname 'Triple G.' In phase 2 trials, participants lost up to 24% of body weight at the highest dose, making it potentially the most powerful weight loss peptide ever studied. The glucagon component adds direct fat-burning and liver fat reduction beyond what GLP-1 alone achieves.

When to Choose Tirzepatide

• You want an FDA-approved dual agonist with robust clinical data
• You prefer a well-established dosing and titration protocol
• Your weight loss goals are achievable with dual agonist therapy
• You want a balance of efficacy and safety profile

When to Choose Retatrutide

• You want maximum weight loss potential (triple mechanism)
• Liver fat reduction is a key goal
• You haven't achieved target results with dual agonist therapy
• You're comfortable with investigational-stage peptides